Table 4.
AEs occurring in ≥10% of patients per group (safety population)
| Celecoxib, n (%) (n=53) | Placebo, n (%) (n=48) | |
|---|---|---|
| Headache | 16 (30.2) | 14 (29.2) |
| Abdominal pain | 9 (17.0) | 10 (20.8) |
| Vomiting | 9 (17.0) | 9 (18.8) |
| Nausea | 8 (15.1) | 8 (16.7) |
| Cough | 8 (15.1) | 6 (12.5) |
| Abdominal discomfort | 9 (17.0) | 4 (8.3) |
| Oropharyngeal pain | 6 (11.3) | 5 (10.4) |
| Diarrhea | 6 (11.3) | 4 (8.3) |
| Fatigue | 6 (11.3) | 4 (8.3) |
| Nasopharyngitis | 6 (11.3) | 4 (8.3) |
| Upper respiratory tract infection | 4 (7.5) | 9 (18.8) |
| Influenza | 6 (11.3) | 1 (2.1) |
| Seasonal allergy | 2 (3.8) | 5 (10.4) |
Abbreviation: AEs, adverse events.